Cargando…
Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
AIMS: This study aimed to describe baseline characteristics of patients with atrial fibrillation (AF) at risk of stroke with and without history of heart failure (HF) and report 2‐year outcomes in the dabigatran‐treated subset of a prospective, global, observational study (GLORIA‐AF). METHODS AND RE...
Autores principales: | Dubner, Sergio J., Teutsch, Christine, Huisman, Menno V., Diener, Hans‐Christoph, Halperin, Jonathan, Rothman, Kenneth J., Ma, Chang‐Sheng, Chuquiure‐Valenzuela, Eduardo, Bergler‐Klein, Jutta, Zint, Kristina, Riou França, Lionel, Lu, Shihai, Paquette, Miney, Lip, Gregory Y.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524082/ https://www.ncbi.nlm.nih.gov/pubmed/32613745 http://dx.doi.org/10.1002/ehf2.12857 |
Ejemplares similares
-
Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA‐AF registry
por: Ma, Changsheng, et al.
Publicado: (2020) -
Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF
por: van der Wall, Sake J., et al.
Publicado: (2021) -
Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry
por: Mazurek, Michał, et al.
Publicado: (2017) -
Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up
por: Kozieł, Monika, et al.
Publicado: (2020) -
Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program
por: Beier, Lea, et al.
Publicado: (2022)